- Home
- QNRX vs ALZN Comparison
QNRX vs ALZN Comparison
Compare QNRX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNRX | ALZN |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QNRX | ALZN |
|---|---|---|
| Price | $4.02 | $1.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $20.71 | N/A |
| AVG Volume (30 Days) | ★ 36.0K | 36.0K |
| Earning Date | 11-05-2026 | 12-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.25 | $0.84 |
| 52 Week High | $23.50 | $2.68 |
Technical Indicators
Market Signals| Indicator | QNRX | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 27.87 |
| Support Level | $3.25 | $1.04 |
| Resistance Level | $5.18 | $1.25 |
| Average True Range (ATR) | 0.36 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 9.09 | 8.95 |
Price Performance
Historical ComparisonAbout QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.